Vizsgálati helyszín
Tufts Children's Hospital
Boston, Massachusetts 02111, Egyesült ÁllamokMég nincs intézményhez kötve
- 20futó vizsgálat
- 15lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 36 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis27 vizsgálat
- 2. fázis6 vizsgálat
- 1. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz20 vizsgálat
- Lezárult15 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Children's Oncology Group24 vizsgálat
- National Cancer Institute (NCI)12 vizsgálat
Futó vizsgálatok
Fut, nem toboroz
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· 3. fázis· Children's Oncology Group· Forrás
Toboroz
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· 2. fázis· Children's Oncology Group· Forrás
Toboroz
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398· 2. fázis· Children's Oncology Group· Forrás
Toboroz
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· 3. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· 2. fázis· Children's Oncology Group· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493· 3. fázis· Children's Oncology Group· Forrás
Toboroz
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Forrás
Fut, nem toboroz
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967· 3. fázis· Children's Oncology Group· Forrás
Lezárt vizsgálatok
Lezárult
Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer
NCT03223753· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02828358· 2. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
NCT01798004· 1. fázis· Children's Oncology Group· Forrás
Lezárult
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883049· 3. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01371981· 3. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
NCT01236560· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Lezárult
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
NCT01190930· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT01096368· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
NCT00945009· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00557193· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
NCT00336024· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
NCT00379340· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
NCT00352534· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
NCT00085735· 3. fázis· Children's Oncology Group· Forrás
Lezárult
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
NCT00026312· 3. fázis· National Cancer Institute (NCI)· Forrás
Hibát jelzek